GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galapagos NV (FRA:GXE) » Definitions » Shiller PE Ratio

Galapagos NV (FRA:GXE) Shiller PE Ratio : (As of May. 03, 2025)


View and export this data going back to 2005. Start your Free Trial

What is Galapagos NV Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Galapagos NV Shiller PE Ratio Historical Data

The historical data trend for Galapagos NV's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galapagos NV Shiller PE Ratio Chart

Galapagos NV Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Galapagos NV Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Galapagos NV's Shiller PE Ratio

For the Biotechnology subindustry, Galapagos NV's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Galapagos NV's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Galapagos NV's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Galapagos NV's Shiller PE Ratio falls into.


;
;

Galapagos NV Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Galapagos NV's E10 for the quarter that ended in Mar. 2025 is calculated as:

For example, Galapagos NV's adjusted earnings per share data for the three months ended in Mar. 2025 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=-2.33/134.3475*134.3475
=-2.330

Current CPI (Mar. 2025) = 134.3475.

Galapagos NV Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201506 -0.590 100.107 -0.792
201509 -0.720 100.245 -0.965
201512 -1.540 100.572 -2.057
201603 0.790 101.653 1.044
201606 -0.100 102.267 -0.131
201609 -0.530 102.118 -0.697
201612 0.970 102.614 1.270
201703 -0.290 103.972 -0.375
201706 -0.710 103.902 -0.918
201709 -0.730 104.170 -0.941
201712 -0.590 104.804 -0.756
201803 -0.730 105.419 -0.930
201806 -0.420 106.063 -0.532
201809 0.280 106.618 0.353
201812 0.300 107.252 0.376
201903 -0.890 107.876 -1.108
201906 -0.860 107.896 -1.071
201909 6.030 107.470 7.538
201912 -2.170 108.065 -2.698
202003 -0.780 108.550 -0.965
202006 -1.770 108.540 -2.191
202009 -1.250 108.441 -1.549
202012 -0.880 108.511 -1.090
202103 0.140 109.522 0.172
202106 -0.980 110.305 -1.194
202109 -0.990 111.543 -1.192
202112 0.250 114.705 0.293
202203 -0.200 118.620 -0.227
202206 -0.290 120.948 -0.322
202209 0.330 124.120 0.357
202212 -3.160 126.578 -3.354
202303 0.350 126.528 0.372
202306 0.080 125.973 0.085
202309 0.390 127.083 0.412
202312 2.390 128.292 2.503
202403 1.370 130.552 1.410
202406 0.140 130.691 0.144
202409 -0.770 130.968 -0.790
202412 0.380 132.346 0.386
202503 -2.330 134.348 -2.330

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Galapagos NV  (FRA:GXE) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Galapagos NV Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Galapagos NV's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Galapagos NV Business Description

Address
Generaal De Wittelaan L11 A3, Mechelen, BEL, 2800
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.

Galapagos NV Headlines

No Headlines